Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial NADH:ubiquinone oxidoreductase (Complex I) is the largest and first enzyme complex of the mitochondrial respiratory chain, located in the inner mitochondrial membrane. It catalyzes the oxidation of NADH to NAD⁺ and transfers electrons to ubiquinone (coenzyme Q10), coupled to the translocation of protons across the membrane. This process is essential for oxidative phosphorylation and ATP production. Complex I is composed of 44 subunits in mammals and plays key roles in cellular energy metabolism, generation of mitochondrial membrane potential, and regulation of oxidative stress. Mutations or dysfunctions in this complex are implicated in numerous human diseases including mitochondrial encephalopathies, Parkinson’s disease, and cardiac and neurological disorders linked to oxidative stress and impaired energy metabolism[1][3][4][5][6][7][9].
Inhibition of electron transfer, Disruption of proton translocation, Modulation of ROS production
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial NADH:ubiquinone oxidoreductase (Complex I).